Technology platform for development of multi-component preservation solution


Principal Investigator: Allison Hubel
Abstract: DESCRIPTION (provided by applicant): Cell therapy products is >$1 billion market with aggressive annual growth rates (15- 20%). Of all of the cells therapies currently in development, mesenchymal stem cells (MSCs) appear to have the greatest diversity of applications and potential for widespread use. Mesenchymal stem/stromal cells (MSCs) are being investigated for a variety of applications. Currently, over 200 clinical trials involve the use of MSCs and over 2000 patients have been safely treated with MSCs. MSCs are being investigated for treatment of cardiovascular disorders (stroke, myocardial infarction), diabetes, connective tissue disorders (cartilage defects, osteonecrosis, limb ischemia), chronic obstructive pulmonary disease, nervous system disorders (multiple sclerosis, Parkinson Disease, spinal cord injury), kidney diseases and more. Current methods for the preservation of MSCs are suboptimal. Improper methods of preservation are felt to have contributed to a recent failure of a Phase III clinical tral. In addition, the infusion of DMSO-containing cells is associated with adverse events that have been well documented in the clinical literature. Clinical and commercial application of MSCs will require the development of protocols that produce a consistent number of viable and functional cells. The proposed investigation transforms not only the preservation protocol for MSCs but creates a new paradigm by which preservation protocols for other cell types can be developed. We propose to use synergy between multiple preservation compounds to improve preservation outcome and replace conventional toxic cryoprotective agents such as DMSO. Testing solutions using multiple compounds would normally require thousands of experiments. We accelerate the convergence of the studies using a computational algorithm. Finally, we will use molecular dynamics to understand molecular mechanisms of action and rationally select compounds appropriate for testing. This type of approach will be applied first of all to MSCs but can be extended to a variety of different cell types used therapeutically. !
Funding Period: 2013-08-01 - 2015-07-31
more information: NIH RePORT

Research Grants

Detail Information

Research Grants31

  1. Diverse Roles of Reactive Oxygen Species and Inflammation in Vascular Disease
    Kathy K Griendling; Fiscal Year: 2013
    ..Ultimately, this research may establish new unifying concepts linking conditions that alter vascular oxidant stress and inflammation to the molecular processes underlying vasculopathies. (End of Abstract) ..
    Timothy Turner; Fiscal Year: 2013
    ..abstract_text> ..
  3. North American Mitochondrial Disease Consortium (NAMDC)
    JOHN L THOMPSON; Fiscal Year: 2013
  4. University of Maryland Greenebaum Cancer Center Support Grant
    Kevin J Cullen; Fiscal Year: 2013
    ..Reflecting our remarkable and continued growth, UMGCC seeks to renew its CCSG to enhance and expand its efforts in high-quality and clinically relevant cancer research. ..
  5. Novel Therapies for Muco-Obstructive Lung Diseases
    RICHARD CHARLES BOUCHER; Fiscal Year: 2013
    ..abstract_text> ..
  6. Assessing a Novel Paradigm of Inducing Cryotolerance
    Ram Devireddy; Fiscal Year: 2013
    ..e., the viability of the cryopreserved adult stem cells (ASCs), in the undifferentiated, adipocyte- or osteoblast- differentiated states, can be improved by increasing the pre-freeze expression of heat shock proteins (HSPs). ..
  7. Pathophysiology of Alveolar Epithelial Lung Injury
    Jacob I Sznajder; Fiscal Year: 2013
    ..The insights gained from the data generated from these studies will provide novel molecular targets for the development of new therapeutic strategies to treat patients with lung injury. ..
  8. Blood Pressure Regulation: Novel Roles for the Kidney
    Pablo A Ortiz; Fiscal Year: 2013
    ..Thus it will accelerate acquisition of knowledge of the novel mechanisms by which the kidney regulates blood pressure, and may provide new targets for anti-hypertensive drugs. ..
  9. Cell Characterization and Imaging for Regenerative Therapies in Ischemic Diseases
    PHILLIP CHUNG MING YANG; Fiscal Year: 2013
    ..We intend to correlate these subsets with clinical endpoints in our PAD and CAD research protocols, to determine what cell subsets may be most critical for any observed benefit. ..
  10. IPF Fibroblast Phenotype
    Craig A Henke; Fiscal Year: 2013
    ..A major objective of this Program Project is to inform decisions of the IPF Clinical Network by providing information that can be translated into novel therapeutic strategies for IPF. ..
  11. Improving Cardiac Function After Myocardial Infarction
    Steven R Houser; Fiscal Year: 2013
    ..A gene vector core will generate AAV6 vectors with novel therapeutics for testing in the pig Ml model. An administrative core will ensure data sharing and effective use of all resources. ..